We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 276

Federal Circuit reverses unreasonable PTAB claim construction, upholds idle free standard for motions to amend
  • Foley & Lardner LLP
  • USA
  • June 23 2015

The Federal Circuit decision in Microsoft Corp. v. Proxyconn, Inc., addressed several important issues relating to post-grant patent trials conducted


Federal Circuit strikes final blow to Celebrex patent
  • Foley & Lardner LLP
  • USA
  • June 25 2015

In 2008, the Federal Circuit determined that claims 1-4 and 11-17 of U.S. Patent No. 5,760,068 were invalid for obviousness-type double patenting


Federal Circuit hold Sequenom diagnostic method patent invalid under 101
  • Foley & Lardner LLP
  • USA
  • June 15 2015

The Federal Circuit has issued its decision in Ariosa Diagnostic, Inc. v. Sequenomn, Inc., affirming the district court's finding that


Federal Circuit finds no direct infringement of Akamai patents
  • Foley & Lardner LLP
  • USA
  • May 19 2015

The Federal Circuit issued its remand decision in Akamai Technologies, Inc. v. Limelight Networks, Inc., this time affirming the district court


Federal Circuit remands Sequenom Down Syndrome test platform patent for consideration under Myriad
  • Foley & Lardner LLP
  • USA
  • August 12 2013

In Aria Diagnostics, Inc. v. Sequenom, Inc., the Federal Circuit vacated and remanded the district court's decision denying Sequenom's motion for a


Federal Circuit finds nunc pro tunc agreement does not confer standing
  • Foley & Lardner LLP
  • USA
  • June 9 2015

The tenuous nature of an exclusive licensee's standing to enforce a patent was something I learned early in my legal career, when I was a judicial


Patent safe harbor applies to supplemental new drug applications
  • Foley & Lardner LLP
  • USA
  • May 21 2015

On May 13, 2015, the Federal Circuit confirmed in Classen Immunotherapies, Inc. v. Elan Pharmaceuticals, Inc. that the safe harbor provisions of 35 U


Dependent claims give rise to improper broadening reissue
  • Foley & Lardner LLP
  • USA
  • May 27 2015

In ArcelorMittal France v. AK Steel Corp., the Federal Circuit found that the addition of a dependent claim to a reissue application improperly


Federal Circuit looks for inventive concept in Sequenom patent
  • Foley & Lardner LLP
  • USA
  • November 10 2014

On November 7, 2014, the Federal Circuit heard oral arguments in Aria Diagnostics, Inc. v. Sequenom, Inc., where Sequenom is appealing the district


Third time is the charm for WildTangent challenge of patent eligibility of Ultramercial patent
  • Foley & Lardner LLP
  • USA
  • November 17 2014

In its third opinion reviewing the same district court decision, the Federal Circuit this time affirmed the district court's grant of WildTangent's